metoclopramide has been researched along with olanzapine in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (23.53) | 29.6817 |
| 2010's | 8 (47.06) | 24.3611 |
| 2020's | 5 (29.41) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Ahman, M; Holmén, AG; Wan, H | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Navari, RM | 1 |
| Gray, SE; Nagy, CK; Navari, RM | 1 |
| Ando, Y; Gyawali, B; Hasegawa, Y; Honda, K; Maeda, O; Matsumoto, M; Sugishita, M; Tsukuura, H; Urakawa, H | 1 |
| Burton, MJ; Head, K; Naessens, K; Plugge, E; Sutherland, A; Ware, L; Wee, B | 1 |
| Frandsen, K; Groenvold, M; Harder, S; Herrstedt, J; Isaksen, J; Jespersen, BA; Mondrup, L; Neergaard, MA; Sigaard, J | 1 |
| Groenvold, M; Harder, S; Herrstedt, J | 1 |
| Dhanushkodi, M; Ganesan, T; Karunakaran, P; Mehra, N; Pai, V; Perumal Kalaiyarasi, J; Radhakrishnan, V; Rajan, AK; Rajaraman, S; Ranganathan, R; Sagar, TG; Selvarajan, G | 1 |
| Imai, K; Ishiki, H; Iwase, S; Kanai, Y; Kaneishi, K; Kohara, H; Morita, T; Nishimura, K; Oyamada, S; Sakurai, N; Yamaguchi, T | 1 |
| Deguchi, Y; Inoue, K; Itoh, Y; Sakamoto, S; Uchida, S | 1 |
| Brunette, ND; Chinn, E; Cole, JB; DeVries, P; Driver, BE; Klein, LR; Miner, JR; Mojica, E; Raiter, A; Stang, JL | 1 |
3 review(s) available for metoclopramide and olanzapine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Prevention of emesis from multiple-day and high-dose chemotherapy regimens.
Topics: Antiemetics; Antineoplastic Agents; Benzodiazepines; Drug Therapy, Combination; Humans; Isoquinolines; Metoclopramide; Neurokinin-1 Receptor Antagonists; Olanzapine; Palonosetron; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Vomiting | 2007 |
Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults.
Topics: Adult; Antiemetics; Antineoplastic Agents; Benzodiazepines; Chemoradiotherapy; Dexamethasone; Disorders of Excessive Somnolence; Fatigue; Humans; Metoclopramide; Nausea; Neoplasms; Olanzapine; Quality of Life; Randomized Controlled Trials as Topic; Vomiting | 2018 |
2 trial(s) available for metoclopramide and olanzapine
| Article | Year |
|---|---|
The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Benzodiazepines; Cisplatin; Cyclophosphamide; Dexamethasone; Double-Blind Method; Doxorubicin; Female; Humans; Isoquinolines; Male; Metoclopramide; Middle Aged; Morpholines; Nausea; Neoplasms; Olanzapine; Palonosetron; Quinuclidines; Vomiting | 2013 |
Olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced vomiting in children: An open-label, randomized phase 3 trial.
Topics: Adolescent; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Male; Metoclopramide; Neoplasms; Olanzapine; Prognosis; Vomiting | 2020 |
12 other study(ies) available for metoclopramide and olanzapine
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Prophylactic Use of Antiemetics for Prevention of Opioid-Induced Nausea and Vomiting: A Questionnaire Survey among Japanese Physicians.
Topics: Analgesics, Opioid; Antiemetics; Benzodiazepines; Chemoprevention; Domperidone; Health Care Surveys; Humans; Japan; Metoclopramide; Nausea; Neoplasms; Olanzapine; Pain; Practice Patterns, Physicians'; Prochlorperazine; Steroids; Vomiting | 2015 |
The nature of nausea: prevalence, etiology, and treatment in patients with advanced cancer not receiving antineoplastic treatment.
Topics: Adrenal Cortex Hormones; Adult; Age Factors; Aged; Aged, 80 and over; Antiemetics; Female; Humans; Male; Metoclopramide; Middle Aged; Nausea; Neoplasms; Olanzapine; Prevalence; Prospective Studies; Sex Factors; Surveys and Questionnaires; Vomiting | 2019 |
Reply to: Olanzapine: Sancho Panza for clinicians who care for patients with advanced cancer.
Topics: Antiemetics; Humans; Male; Metoclopramide; Nausea; Neoplasms; Olanzapine; Vomiting | 2020 |
Olanzapine versus Metoclopramide for Treatment of Nausea and Vomiting in Advanced Cancer Patients with Incomplete Malignant Bowel Obstruction.
Topics: Antiemetics; Double-Blind Method; Humans; Metoclopramide; Nausea; Neoplasms; Olanzapine; Vomiting | 2020 |
Prolonged extrapyramidal symptoms induced by long-term, intermittent administration of low-dose olanzapine along with metoclopramide for emesis: A case report.
Topics: Antiemetics; Antineoplastic Agents; Antipsychotic Agents; Biperiden; Clonazepam; Dopamine; Humans; Male; Metoclopramide; Middle Aged; Olanzapine; Palonosetron; Psychomotor Agitation; Quetiapine Fumarate; Sleep Initiation and Maintenance Disorders; Vomiting | 2022 |
Comparison of efficacy and frequency of akathisia and dystonia between olanzapine, metoclopramide and prochlorperazine in ED headache patients.
Topics: Cohort Studies; Double-Blind Method; Dystonia; Emergency Service, Hospital; Headache; Humans; Metoclopramide; Migraine Disorders; Olanzapine; Prochlorperazine; Psychomotor Agitation | 2023 |